in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharma/fine chemicals roundup—26 November 2013
5:53 AM MST | November 26, 2013 | Deepti Ramesh
Johnson Matthey’s fine chemicals division reports rise in sales The fine chemicals division of Johnson Matthey (London), which comprises the company's active pharmaceutical ingredient (API) manufacturing business, the catalysis and chiral technologies business, and research chemicals, generated revenue of £185 million ($298 million), in its fiscal first half ended 30 September 2013, up 8% year-on-year (YOY). Sales from the division’s API-manufacturing business increased by 7%, to £105 million. Sales in the research chemicals business...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee